Ch14.18/CHO
Phase 1Small molecule
Ch14.18/CHO is one of 53 small molecule programs targeting Neuroblastoma. It is currently in Phase 1.
1
Indications
5
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Neuroblastoma
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Paraplatin
AAvyxa
Phase 3
Vepesid
AAvyxa
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Camptosar
PfizerPhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Alkeran
AApotex Inc.
Phase 3
Accutane
CConrado Roberto Hoffmann Filho
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Oncovin
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuroblastoma3 trials
Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
Active, not recruiting·UUniversity Hospital Southampton NHS Foundation Trust·Phase 1·NCT02914405·44 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ch14.18/CHO. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSt. Anna Kinderkrebsforschung